LYON, France--(BUSINESS WIRE)-- Regulatory News:

POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today informs its shareholders that the Annual General Meeting (AGM) will be held on November 28, 2024, at the Mercure Lyon Centre Château Perrache Hotel, located at 12 Cours de Verdun-Rambaud Esplanade de la Gare, 69002 Lyon, and provides information on voting procedures.

Shareholders willing to follow the AGM but unable to attend in person are invited to connect via the following link (the AGM will be held in French): click here.

This live broadcast of the AGM will not allow remote voting or questions via the chat feature on the platform used.

A replay of the AGM will be available on the Company’s website after the meeting.

In accordance with current regulations, Poxel shareholders may cast their votes before the AGM, starting from November 13, 2024, by mail, proxy, or electronically, following the instructions in the meeting notice published in the French BALO (French legal gazette) on October 23, 2024.

The option to vote or grant proxy electronically is available via the secure voting platform Votacess, which will open on November 13, 2024, at 9:00 am (Paris time) and close on November 27, 2024, at 3:00 pm (Paris time).

Voting instructions are also detailed in the practical guide available to shareholders on the Company’s website.

All preparatory documents and information related to this AGM are available to shareholders under legal and regulatory conditions and can be accessed on the Company’s website in the “Annual General Meeting Documents” section.

For any questions regarding voting procedures, you may contact the Investor Relations team by email: investors@poxelpharma.com.

About Poxel SA

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG^® (Imeglimin), Poxel’s first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: www.poxelpharma.com

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241106928619/en/

Investor relations / Media
NewCap
Nicolas Fossiez, Aurélie Manavarere / Arthur Rouillé
investors@poxelpharma.com
+33 1 44 71 94 94

Source: POXEL SA

Released November 7, 2024